ERBB2 and breast carcinoma: For example, mAbs like rituximab (targeting Cluster of Differentiation (CD)20 on malignant B lymphocytes) and trastuzumab (targeting Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer) work by mediating tumor cell lysis through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).